Home > Insider Trading > Filing (0000899243-20-009605)

Filing Details

Accession Number:: 0000899243-20-009605
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-26 21:00:29
Reporting Period:: 2020-03-24

Accepted Time:: 2020-03-26 21:00:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1571498	Epizyme Inc.	EPZM	Pharmaceutical Preparations (2834)	261349956

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1620152	B Robert Bazemore	C/O Epizyme, Inc. 400 Technology Square Cambridge MA 02139	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, Par Value $0.0001	Disposition	2020-03-24	56,537	$0.00	80,726	No	4	J	Direct
Common Stock, Par Value $0.0001	Acquisiton	2020-03-24	113,393	$0.00	250,656	No	4	A	Direct
Common Stock, Par Value $0.0001	Acquisiton	2020-03-24	7,000	$0.00	257,656	No	4	A	Direct
Common Stock, Par Value $0.0001	Disposition	2020-03-25	3,285	$15.28	254,371	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	J	Direct
No	4	A	Direct
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-03-24	79,167	$0.00	79,167	$8.98
Common Stock	Stock Option (Right to Buy)	Disposition	2020-03-24	2,371	$0.00	2,371	$12.45
Common Stock	Stock Option (Right to Buy)	Disposition	2020-03-24	48,727	$0.00	48,727	$9.12
Common Stock	Stock Option (Right to Buy)	Acquisiton	2020-03-24	73,409	$0.00	73,409	$16.14

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
333,333	2026-02-07	No	4	J	Direct
333,333	2027-02-07	No	4	J	Direct
298,737	2029-01-23	No	4	J	Direct
73,409	2030-03-23	No	4	A	Direct

Footnotes

Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants.
Consists of shares of common stock issuable under restricted stock units granted pursuant to the Company's 2013 Stock Incentive Plan. Each restricted stock unit represents the right to receive one share of common stock upon vesting. 56,537 of the restricted stock units are scheduled to vest in three equal annual installments on January 24, 2021, January 24, 2022 and January 24, 2023. The balance of the restricted stock units are scheduled to vest in two equal annual installments over two years from the grant date.
Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved.
Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 6. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person.
The remaining stock options, which were originally granted to Mr. Bazemore on February 8, 2016, have vested in full.
The remaining stock options, which were originally granted to Mr. Bazemore on February 8, 2017, are vested with respect to 258,771 shares, with (i) 69,939 of the remaining unvested shares vesting in ten substantially equal monthly installments from April 8, 2020 through January 8, 2021 and (ii) 4,623 of the remaining shares vesting on February 8, 2021.
The remaining stock options, which were originally granted to Mr. Bazemore on January 24, 2019, are vested with respect to 101,343 shares, with (i) 188,210 of the remaining unvested shares vesting in 26 substantially equal monthly installments from April 24, 2020 through May 24, 2022 (ii) 1,945 of the remaining unvested shares vesting on June 24, 2022 and (iii) 7,239 of the remaining unvested shares vesting on January 24, 2023.
This stock option was granted on March 24, 2020 under the Company's 2013 Stock Incentive Plan and (i) is vested in full with respect to 44,047 shares, (ii) vests in full on February 8, 2021 with respect to 1,829 shares and (iii) with respect to the remaining 27,533 shares of common stock, vests in seven substantially equal monthly installments, with the first installment vesting on June 24, 2022 and the last installment vesting on December 24, 2022.